<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>20</Volume>
				<Issue>8</Issue>
				<PubDate PubStatus="epublish">
					<Year>2019</Year>
					<Month>08</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Gene Combination of CD44 rs187116, CD133 rs2240688, NF-κB1 rs28362491 and GSTM1 Deletion as a Potential Biomarker in Risk Prediction of Breast Cancer in Lower Northern Thailand</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>2493</FirstPage>
			<LastPage>2502</LastPage>
			<ELocationID EIdType="pii">88696</ELocationID>
			
<ELocationID EIdType="doi">10.31557/APJCP.2019.20.8.2493</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Kamonpat </FirstName>
					<LastName>Sapcharoen</LastName>
<Affiliation>Department of Biochemistry, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand.</Affiliation>

</Author>
<Author>
					<FirstName>Phanchana </FirstName>
					<LastName>Sanguansermsri</LastName>
<Affiliation>Department of Biochemistry, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand.</Affiliation>

</Author>
<Author>
					<FirstName>Sukkid </FirstName>
					<LastName>Yasothornsrikul</LastName>
<Affiliation>Department of Biochemistry, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand.</Affiliation>

</Author>
<Author>
					<FirstName>Kanha </FirstName>
					<LastName>Muisuk</LastName>
<Affiliation>Department of Forensic Medicine,
Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.</Affiliation>

</Author>
<Author>
					<FirstName>Metawee </FirstName>
					<LastName>Srikummool</LastName>

						<AffiliationInfo>
						<Affiliation>Department of Biochemistry, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand.</Affiliation>
						</AffiliationInfo>

						<AffiliationInfo>
						<Affiliation>Center of Excellence in Medical Biotechnology, Faculty of Medical
Science, Naresuan University, Phitsanulok, Thailand.</Affiliation>
						</AffiliationInfo>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2019</Year>
					<Month>06</Month>
					<Day>15</Day>
				</PubDate>
			</History>
		<Abstract>Background: Biomarkers play an important role in oncology, including risk assessment, treatment prediction, and&lt;br /&gt;monitoring the progression of disease. In breast cancer, many genes are used as biomarkers. Since, several SNP variations&lt;br /&gt;of hallmark – related genes have been reported to be of value in risk prediction in various cancers and populations, some&lt;br /&gt;genetic polymorphism loci were combined and reported as biomarkers for use in the risk assessment of breast cancer&lt;br /&gt;in Thai people. Methods: Twelve cancer gene hallmarks (15 polymorphic loci) were selected and genotyped in 184&lt;br /&gt;breast cancer patients and 176 healthy individuals in Phitsanulok, Thailand. Results: AA genotype of CD44 rs187116&lt;br /&gt;(c.67+4883G&gt;A), the C allele of CD133 rs2240688 (c.*667A&gt;C), the *2 allele (4 bp deletion) of NF-κB1 rs28362491&lt;br /&gt;and the homozygous null allele genotype of GSTM1 were significantly associated with an increased risk of breast cancer&lt;br /&gt;(p&lt;0.05). A combination of these 4 significant loci showed that AA-AA-*1*1-homozygous null allele genotype has the&lt;br /&gt;greatest correlation with increased risk of breast cancer (OR = 21.00; 95% CI: 1.77 to 248.11; p = 0.015), followed by&lt;br /&gt;GA-AA-*2*2- homozygous null allele genotype (p = 0.037) and GG-AC-*1*2- homozygous null allele genotype (p&lt;br /&gt;= 0.028). Conclusion: These findings suggest that the polymorphisms of CD44 rs187116 (c.67+4883G&gt;A), CD133&lt;br /&gt;rs2240688 (c.*667A&gt;C), NF-κB1 rs28362491 and GSTM1 homozygous null allele genotype might be associated with&lt;br /&gt;an increased risk of breast cancer, and this gene combination could possibly be used as biomarkers for risk prediction,&lt;br /&gt;which would be of benefit in planning health surveillance and cancer prevention.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">breast cancer</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Cancer surveillance</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Genetic biomarker</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Polymorphism</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_88696_d174632afbf51999a9459ac2ded9536f.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
